Jan Westin (Former)
1 – 18 of 18
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Diagnostik och uppföljning av patienter med små M-komponenter. Med sikte på att undvika transformation till malign sjukdom.
(
- Contribution to journal › Scientific review
- 2008
-
Mark
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
(
- Contribution to journal › Article
- 2006
-
Mark
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
(
- Contribution to journal › Article
-
Mark
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
(
- Contribution to journal › Article
- 2005
-
Mark
Management of patients with polycythaemia vera: results of a survey among Swedish haematologists
(
- Contribution to journal › Article
-
Mark
Nordic Myeloma Study Group, the first 15 years: Scientific collaboration and improvement of patient care
(
- Contribution to journal › Scientific review
-
Mark
Frustration över arbetsvillkoren hos svenska verksamhetschefer
(
- Contribution to journal › Article
-
Mark
International Staging System for Multiple Myeloma.
(
- Contribution to journal › Article
- 2004
-
Mark
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
(
- Contribution to journal › Article
-
Mark
MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
(
- Contribution to journal › Article
-
Mark
High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.
(
- Contribution to journal › Article
-
Mark
Physicians as clinical directors: working conditions, psychosocial resources and self-rated health.
(
- Contribution to journal › Article
-
Mark
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders
(
- Contribution to journal › Article
- 2003
-
Mark
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
(
- Contribution to journal › Article
-
Mark
Patientspecifik kostnadsberäkning i sjukvården - bra bas för att värdera nya behandlingsmetoder
(
- Contribution to journal › Article
-
Mark
A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.
(
- Contribution to journal › Article
- 2002
-
Mark
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
(
- Contribution to journal › Article
- 1998
-
Mark
Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma
(
- Contribution to journal › Article